sprite-preloader
Anzeige
Mehr »
Dienstag, 19.03.2019 Börsentäglich über 12.000 News von 601 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

WKN: A2AG0F ISIN: SE0006091997 Ticker-Symbol: 1YR 
Aktie:
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
IMMUNOVIA AB Chart 1 Jahr
1-Woche-Intraday-Chart
IMMUNOVIA AB 1-Woche-Intraday-Chart

Aktuelle News zu IMMUNOVIA Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:
LeserMedien
04.03.Immunovia Publishes the Annual Report for the Financial Year 20182
LUND, Sweden, March 4, 2019 /PRNewswire/ -- Immunovia has today published the annual report for 2018 in Swedish. It is available on Immunovia's website. Mats Grahn, CEO, comments: "We...
► Artikel lesen
IMMUNOVIA Aktien ab 5,80 Euro handeln - Ohne versteckte Kosten!

► Artikel lesen
04.03.Immunovia Provides an Update on the Optimization Work to Meet the Expected Performance for Commercialization of IMMray PanCan-d2
LUND, SWEDEN, March 4, 2019 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia") today announced an update on the optimization process to refine the algorithms and eliminate any potential variations...
► Artikel lesen
15.02.BRIEF-Immunovia Q4 Pretax Loss Widens To SEK 25.7 Mln1

► Artikel lesen
14.02.Immunovia Full Year Report, January-December 20182
STOCKHOLM, Feb. 14, 2019 /PRNewswire/ -- Throughout 2018, we continued to build on our mission to develop and validate accurate bloodbased diagnostic tests that can make a real and...
► Artikel lesen
14.02.Immunovia to Participate in Upcoming Investor Conferences in March1
LUND, Sweden, Feb. 14, 2019 /PRNewswire/ -- Immunovia AB today announced that Mats Grahn, Chief Executive Officer, will participate and host one-on-one investor meetings at the following...
► Artikel lesen
12.02.Invitation to Presentation of Immunovia's Full Year Report 2018 on February 14, 20192
LUND, Sweden, Feb. 12, 2019 /PRNewswire/ -- Immunovia invites to a teleconference (in English) for investors, analysts and media on February 14, at 5:30 - 6:30 p.m. CET. Immunovia will...
► Artikel lesen
12.02.Immunovia AB Announces Appointment of Senior Director of Investor Relations2
LUND, Sweden, Feb. 12, 2019 /PRNewswire/ -- (Nasdaq Stockholm: IMMNOV), to strengthen IR and shareholder communication Immunovia today announced that Julie Silber has joined as Director...
► Artikel lesen
13.11.18Immunovia Invited to Present at Jefferies 2018 London Healthcare Conference1
LUND, Sweden, Nov. 13, 2018 /PRNewswire/ -- Immunovia (Nasdaq Stockholm: IMMNOV), today announced that the Company has been invited to present at the Jefferies 2018 London Healthcare Conference...
► Artikel lesen
07.11.18Immunovia Interim Report January-September 20182
STOCKHOLM, Nov. 7, 2018 /PRNewswire/ -- Immunovia's IMMray platform for blood-based biomarker signatures offers exciting new opportunities to develop accurate diagnostic tests that can detect...
► Artikel lesen
06.11.18Immunovia Sponsors Primary Care Educational Symposium at Fenway Park in Honor of World Pancreatic Cancer Day1
MARLBOROUGH, Massachusetts, Nov. 6, 2018 /PRNewswire/ -- On November 15, 2018 Immunovia will sponsor a unique educational symposium for primary care clinicians in honor of World Pancreatic...
► Artikel lesen
05.11.18Invitation to Presentation of Immunovia's Interim Report January-September 2018 on November 7, 20184
LUND, Sweden, Nov 5, 2018 /PRNewswire/ -- Immunovia will publish the company's interim report for the period January-September 2018 on Wednesday, November 7, at 08:30 a.m. CET. Immunovia...
► Artikel lesen
26.10.18Immunovia AB (Publ) Nomination Committee Appointed for AGM 20191
According to the instruction that was adopted at the Immunovia AB (Publ) AGM May 3 2018, the nomination committee should consist of four members LUND, Sweden, Oct. 26, 2018 /PRNewswire/...
► Artikel lesen
08.10.18Immunovia Announces Strategic Focus Centered on IMMray Blood-based Biomarker Signatures for Rheumatoid Arthritis Within Autoimmunity7
LUND, Sweden, Oct. 8, 2018 /PRNewswire/ --Encouraged by the promising discovery study results previously reported, Immunovia's prime focus in autoimmunity testing will be to develop IMMray...
► Artikel lesen
04.10.18Immunovia PanFAM-1 Clinical Trial now Available on ClinicalTrials.gov, the Largest Clinical Trials Database in the World2
LUND, Sweden, Oct. 4, 2018 /PRNewswire/ -- Immunovia has developed a blood based biomarker signature for early detection of pancreatic cancer called IMMray PanCan-d. To validate IMMray PanCan-d...
► Artikel lesen
28.09.18Invitation to Conference Call Regarding Immunovia's Autoimmune Diseases Strategy on October 8, 20185
Immunovia invites to a teleconference (in English) for investors, analysts and media on October 8, 2018 at 3:00 - 4:00 p.m CET LUND, Sweden, Sept. 28, 2018 /PRNewswire/ -- Immunovia...
► Artikel lesen
24.08.18Immunovia Interim Report, January-June 20185
STOCKHOLM, Aug. 24, 2018 /PRNewswire/ -- "On 3 April, trading in Immunovia's shares started on NASDAQ Stockholm's main market, where we are listed in the Mid Cap segment. During the second...
► Artikel lesen
23.08.18Invitation to presentation of Immunovia's Interim Report January-June 2018 and Comments to the Previously Published Autoimmunity Study Results2
LUND, Sweden, Aug. 23, 2018 /PRNewswire/ -- Immunovia will publish the company's interim report for the period January-June 2018 on Friday, August 24, at 08:30 a.m. CET. Immunovia invites...
► Artikel lesen
09.08.18Immunovia's Blood-based IMMray Biomarker Array Provides Highly Accurate Diagnosis of non-small Cell Lung Cancer in a New Collaborative Study61
LUND, Sweden, Aug 9, 2018 /PRNewswire/ -- Immunovia AB announced today that in a new collaborative study with a major global pharma company, Immunovia ´s innovative blood-based testing platform...
► Artikel lesen
03.08.18Karolinska Institutet Participates in Immunovia's PanFAM-1 Prospective Clinical Study for Early Detection of Pancreatic Cancer Using Blood-based Test5
Prospects rise for world's first national screening program. STOCKHOLM and LUND, SWEDEN, Aug 3, 2018 /PRNewswire/ -- Immunovia AB today announced that the Karolinska Institutet...
► Artikel lesen
08.06.18Immunovia has Completed a Directed Share Issue of Approximately SEK 324 Million9
STOCKHOLM, June 8, 2018 /PRNewswire/ -- NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA...
► Artikel lesen
Seite:  Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
IMMUNOVIA AB-Investoren interessieren sich auch für diese News

Unternehmen / AktienAktienkurs%Top-Nachrichten
SIEMENS HEALTHINEERS38,00+0,16 %Siemens Healthineers hat Geburtstag
Die seit einem Jahr von Siemens abgespaltene Tochter Healthineers feiert heute ihr Börsendebüt. Jetzt träumt man sogar von einem Aufstieg in den DAX. Am 16. März 2018 kam Siemens Healthineers mit einem...
► Artikel lesen
ECKERT & ZIEGLER85,40-0,23 %adesso, Allgeier, Cyan, Datagroup, Eckert & Ziegler, Fabasoft, Pva Tepla, S&T, Singulus und Vectron im Fokus - Wochenupdate KW 11/2019
Im wikifolio "Top Pics of the Year" soll eine Auswahl von 10 Einzeltiteln zusammengestellt werden, die meines Erachtens für das jeweilige Jahr die größten Renditechancen versprechen. Der Schwerpunkt...
► Artikel lesen
VITA 3413,95+0,72 %Vita 34: Umsatz macht Arbeit, Ergebnis macht Freude
Hamburg (www.aktiencheck.de) - Vita 34-Aktienanalyse von Aktienanalyst Henrik Markmann von der Montega AG: Henrik Markmann, Aktienanalyst der Montega AG, rät in einer aktuellen Aktienanalyse weiterhin...
► Artikel lesen
UMS UNITED MEDICAL SYSTEMS0,61+0,83 %XFRA FRA: DELETION OF INSTRUMENTS FROM XETRA - 21.01.2019
The following instruments on XETRA do have their last trading day on 21.01.2019 Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 21.01.2019 ISIN Name CA0673963090 BARD VENTURES...
► Artikel lesen
EVOFEM BIOSCIENCES3,07+0,99 %Evofem Biosciences, Inc. (EVFM) CEO Saundra Pelletier on Q4 2018 Results - Earnings Call Transcript

► Artikel lesen
Lade...